Point72 Asia Singapore Pte. Ltd. Lowers Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Point72 Asia Singapore Pte. Ltd. trimmed its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 62.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,615 shares of the company's stock after selling 22,929 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Progyny were worth $235,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PGNY. Vanguard Group Inc. lifted its holdings in shares of Progyny by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock valued at $149,939,000 after buying an additional 48,271 shares during the period. Pacer Advisors Inc. lifted its holdings in Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after acquiring an additional 1,183,558 shares during the period. River Road Asset Management LLC purchased a new stake in shares of Progyny during the 4th quarter worth $25,529,000. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares during the period. Finally, Barclays PLC increased its holdings in shares of Progyny by 95.7% in the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock valued at $23,843,000 after purchasing an additional 676,048 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PGNY has been the topic of a number of research analyst reports. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Canaccord Genuity Group reduced their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, May 12th. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $23.45.

Progyny Stock Down 0.2%

Shares of PGNY traded down $0.04 during trading hours on Thursday, reaching $21.16. 216,891 shares of the company traded hands, compared to its average volume of 1,710,021. The stock has a fifty day simple moving average of $22.17 and a 200 day simple moving average of $19.86. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $30.42. The stock has a market capitalization of $1.81 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The firm had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny's revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. Research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.